| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | FLT3; CD135; FLK2; STK1; Receptor-type tyrosine-protein kinase FLT3; FL cytokine receptor; Fetal liver kinase-2; FLK-2; Fms-like tyrosine kinase 3; FLT-3; Stem cell tyrosine kinase 1; STK-1; CD antigen CD135 |
| Entrez GeneID | 2322 |
| WB Predicted band size | Calculated MW: 113 kDa; Observed MW: 110 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | The antiserum was produced against synthesized peptide derived from the Internal region of human FLT3. AA range:451-500 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于CD135(FLT3)抗体的示例参考文献(仅供参考，实际文献需通过学术数据库验证)：
---
1. **文献名称**：*"Development of a monoclonal antibody targeting CD135/FLT3 for acute myeloid leukemia therapy"*
**作者**：Kiyoi H, et al.
**摘要**：该研究报道了一种靶向CD135的单克隆抗体的开发，通过阻断FLT3受体的自磷酸化，抑制下游信号通路(如PI3K/AKT和STAT5)，并在AML小鼠模型中诱导白血病细胞凋亡，减缓疾病进展。
2. **文献名称**：*"FLT3 antibody-drug conjugates exhibit potent antitumor activity in preclinical models of hematopoietic malignancies"*
**作者**：Gill S, et al.
**摘要**：研究构建了CD135抗体与细胞毒性药物的偶联物(ADC)，证明其在FLT3过表达的血液癌细胞系和异种移植模型中能选择性杀伤肿瘤细胞，且对正常造血干细胞影响较小。
3. **文献名称**：*"CD135 antibody-mediated depletion of leukemic stem cells in myelodysplastic syndromes"*
**作者**：Wang L, et al.
**摘要**：通过抗CD135抗体特异性靶向骨髓增生异常综合征(MDS)中的白血病干细胞，实验显示抗体可显著减少干细胞自我更新能力，并增强化疗药物的敏感性。
4. **文献名称**：*"Functional characterization of FLT3 antibodies in modulating hematopoietic progenitor differentiation"*
**作者**：Zhang Y, et al.
**摘要**：研究分析了不同表位的CD135抗体对造血祖细胞分化的影响，发现某些抗体通过激活或抑制FLT3信号通路，可定向调控细胞向特定谱系分化。
---
**注意**：以上为示例性内容，实际文献需通过PubMed、Google Scholar等平台检索确认。建议使用关键词“FLT3 antibody”“CD135 therapeutic”或结合特定应用场景(如白血病、干细胞)进一步筛选。
CD135. also known as FLT3 (FMS-like tyrosine kinase 3), is a class III receptor tyrosine kinase expressed primarily on hematopoietic stem cells, progenitor cells, and certain leukemia cells. It plays a critical role in regulating cell survival, proliferation, and differentiation by binding to its ligand, FLT3LG (FLT3 ligand). CD135 antibodies are essential tools in research and diagnostics, particularly in hematologic malignancies. Mutations in *FLT3*, such as internal tandem duplications (ITD) or tyrosine kinase domain (TKD) mutations, are common in acute myeloid leukemia (AML) and associated with poor prognosis. Antibodies targeting CD135 enable detection of FLT3 expression via flow cytometry, immunohistochemistry, or Western blot, aiding in leukemia subtyping and minimal residual disease monitoring.
Therapeutic CD135-directed agents, including monoclonal antibodies and tyrosine kinase inhibitors (e.g., midostaurin, gilteritinib), are used to block aberrant FLT3 signaling in AML. Research-grade antibodies are validated for specificity, cross-reactivity (species-dependent), and functional applications, such as studying FLT3 activation pathways or drug resistance mechanisms. Additionally, CD135 antibodies are explored in immunotherapies, like CAR-T cells, to target FLT3-positive malignancies. Quality control ensures batch consistency for reliable experimental and clinical outcomes. Overall, CD135 antibodies bridge translational research and precision oncology in hematopoiesis and leukemia therapeutics.
×
